ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NVCT / news
BCAX (30) ZVRA (37) OLMA (29) ANL (46) ⌘ Pro Terminal →

Why NVCT Stock surged +3.79% Today — RQD Quant Desk Flash

$19.18 +3.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.27

Nuvectis Pharma Inc. (NVCT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $602.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NVCT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NVCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nuvectis Pharma Inc. (NASDAQ: NVCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $19.18 (+3.79% 1D, market cap $602.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NVCT ranks #532 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NVCT compare to BCAX and ZVRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVCT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCAX (Bicara Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $604.2M) and ZVRA (Zevra Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NVCT?
▼

Per NVCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875558), Nuvectis Pharma Inc. generated $77.2M in revenue (+38.9% YoY), -$26.4M in net income, and -$16.0M in free cash flow against $31.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.27 (+0.49%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (7)Whales (7)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$31 Bull$17 Base$14 Bear
📬 FREE NVCT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVCT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY NVCT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 41.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$18.15+13.4% Next Q
Q2 (-2Q)
32
Grade E$20.59-10.4% Next Q
Q3 (-1Q)
34
Grade E$18.44+4% Next Q
Current
37
Grade D-$19.18-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NVCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NVCT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.24) and Max Pain ($20.14) forces dealer call-delta covering toward $30.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NVCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why NVCT Stock surged +3.79% Today — RQD Quant Desk Flash

Nuvectis Pharma Inc. (NVCT) surged +3.79% to $19.18, trading at 57% of its 52-week range ($5.55 – $29.27). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 57% of its 52-week range ($5.55 – $29.27) with RSI-14 at 41.5 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $19.18 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NVCT Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVCT)

  • ✓Walkthrough of NVCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NVCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +115.75%⚡ TESTING RESISTANCE
2026-11-03O $18.57H $19.18L $18.48C $19.18VOL 168.9K
RES: $20.77SUP: $17.60SMA50: $21.24SMA200: $14.71
$30.80$24.46$18.11$11.77$5.42RES $20.77SUP $17.60$19.182026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NVCT Butterfly Map → + Track NVCT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +38.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NVCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NVCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NVCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVCT)

Health Care Rank #532 of 1015 ⚔️ BCAX vs NVCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NVCT vs. BCAX, ZVRA, OLMA, ANL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Nuvectis Pharma Inc. (NVCT) ranks #532 by composite RQD confidence (37/100, grade D-) and #415 by equity capitalization ($602.7M). Within this direct 5-issuer industry benchmark cohort, ZVRA leads on earnings valuation at 7.4x trailing P/E, while ZVRA leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with NVCT at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NVCT ACTIVE
Nuvectis Pharma Inc.
D- 37/100 — — -35.0% +3.79% $602.7M Benchmark Subject
BCAX
Bicara Therapeutics Inc.
E 30/100 — — -35.0% -13.14% $604.2M /bcax-vs-nvct →
ZVRA
Zevra Therapeutics Inc.
D- 37/100 7.4x — -32.3% -1.75% $610.5M /zvra-vs-nvct →
OLMA
Olema Pharmaceuticals Inc.
E 29/100 — — -32.8% +1.00% $612.5M /olma-vs-nvct →
ANL
Adlai Nortye Group Ltd.
D 46/100 — — — -1.88% $615.0M /anl-vs-nvct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001875558 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nuvectis Pharma Inc. (NVCT) reported GAAP revenue of $77.2M (+38.9% vs. FY2024 revenue of $55.6M , and +20.4% cumulative change since FY2023) , GAAP net income of -$26.4M, operating cash flow of -$16.0M, and free cash flow of -$16.0M (-30.7% YoY). On the balance sheet, NVCT closed FY2025 with $31.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $77.2M -$26.4M -$16.0M -$16.0M $31.7M —
FY2024 (FY) 2024-12-31 $55.6M -$19.0M -$12.2M -$12.2M $18.6M —
FY2023 (FY) 2023-12-31 $64.1M -$22.3M -$16.0M -$16.0M — —

3. NVCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NVCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nuvectis Pharma Inc. (NASDAQ: NVCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $19.18 (+3.79% 1D, market cap $602.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NVCT ranks #532 in composite RQD confidence.

How does NVCT compare to BCAX and ZVRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NVCT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCAX (Bicara Therapeutics Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $604.2M) and ZVRA (Zevra Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NVCT?

Per NVCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001875558), Nuvectis Pharma Inc. generated $77.2M in revenue (+38.9% YoY), -$26.4M in net income, and -$16.0M in free cash flow against $31.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NVCT trading relative to its 50-day, 200-day, and 52-week technical levels?

NVCT last traded at $19.18 (+3.79% on volume of 213,704 shares), positioning the stock -9.70% below its 50-day simple moving average ($21.24) and +30.39% above its 200-day simple moving average ($14.71). Across its 52-week range of $5.55 to $29.27, NVCT sits at the 57.5% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($16.78 to $21.58).

Direct Sub-Reports: NVCT RQD Cockpit NVCT 12M Forecast NVCT Earnings & Move NVCT Dividends & DRIP NVCT Insiders & 13F NVCT Whale Options NVCT Profit Sankey NVCT News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

NVCT — Nuvectis Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nuvectis Pharma Inc. (NVCT) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $19.18 (+3.79% 1D, market capitalization $602.7M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -2.64%.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nuvectis Pharma Inc. (NVCT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..6B. Per the financials, reported revenue is — for each of the listed periods, indicating no revenue-generating product sales in the source data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nuvectis Pharma Inc. (NVCT) reported $77.2M in annual revenue (up from $55.6M in FY2024, +38.9% YoY) and -$26.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($64.1M revenue, -$22.3M net income) through FY2025, NVCT scaled operating cash flow to -$16.0M and free cash flow to -$16.0M, backed by $31.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.64% and institutional whale pillar of 7/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $5.55 – $29.27 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NVCT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can NVCT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $77.2M and free cash flow of -$16.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NVCT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NVCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nuvectis Pharma Inc. (NVCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NVCT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NVCT Bull vs. Bear Conversation Board — What's Your Call at $19.18?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVCT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NVCT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $22.18 (+20.0%)
📌 Pinned Debate

Positive NXP200 Phase 1b data reported durable and complete responses in BRAF V600-mutated gliomas, with 12-month survival of 95% among

Long NVCT at $18.48 targeting $22.18. Positive NXP200 Phase 1b data reported durable and complete responses in BRAF V600-mutated gliomas, with 12-month survival of 95% among 20 high-grade patients.. Institutional whale score is 7/20 and the risk/reward vs. the $5.55 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — NVCT's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $14.41 (-22.0%)
Spot @ $18.48

The company reported zero revenue, a FY 2025 net loss of -$26.4M, and an ROIC of -35%, with a Piotroski F-Score of 2 out of 9 and a D-

Sitting on the sidelines or leaning short NVCT above $18.48. The company reported zero revenue, a FY 2025 net loss of -$26.4M, and an ROIC of -35%, with a Piotroski F-Score of 2 out of 9 and a D- RQD grade.. Until Fundamental Cash Engine (7/20) and FCF yield (-2.64%) inflect higher, upside is capped near $29.27.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%